Vessel Normalization in the Spot-LIGHT of Cancer Treatment

Manuel Ehling; Massimiliano Mazzone

doi:10.1016/j.molmed.2015.12.009

Vessel Normalization in the Spot-LIGHT of Cancer Treatment

Trends Mol Med. 2016 Feb;22(2):85-87. doi: 10.1016/j.molmed.2015.12.009. Epub 2016 Jan 7.

Authors

Manuel Ehling¹, Massimiliano Mazzone²

Affiliations

¹ Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, VIB, B3000 Leuven, Belgium; Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, Department of Oncology, KU Leuven, B3000 Leuven, Belgium.
² Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, VIB, B3000 Leuven, Belgium; Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, Department of Oncology, KU Leuven, B3000 Leuven, Belgium. Electronic address: [email protected].

PMID: 26774932
DOI: 10.1016/j.molmed.2015.12.009

Abstract

Targeting the aberrant, nonfunctional tumor vasculature is one of the most promising approaches of new anticancer therapies. Here, we discuss a recent publication and a novel mechanism by which tumor-associated macrophages can actively induce vessel normalization and junction stability, and improve the distribution of therapeutic drugs into a tumor.

Keywords: LIGHT; TGFβ; mural cell contractility; pericytes; tumor associated macrophages; tumor blood vessel normalization.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Neoplasms / drug therapy*
Neovascularization, Pathologic / drug therapy*